455 related articles for article (PubMed ID: 29425074)
1. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
Terauchi Y; Sano K; Ainai A; Saito S; Taga Y; Ogawa-Goto K; Tamura SI; Odagiri T; Tashiro M; Fujieda M; Suzuki T; Hasegawa H
Hum Vaccin Immunother; 2018 Jun; 14(6):1351-1361. PubMed ID: 29425074
[TBL] [Abstract][Full Text] [Related]
2. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
[TBL] [Abstract][Full Text] [Related]
3. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
4. Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate.
Ainai A; Suzuki T; Tamura SI; Hasegawa H
Viral Immunol; 2017; 30(6):451-462. PubMed ID: 28650274
[TBL] [Abstract][Full Text] [Related]
5. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.
Ainai A; Tamura S; Suzuki T; Ito R; Asanuma H; Tanimoto T; Gomi Y; Manabe S; Ishikawa T; Okuno Y; Odagiri T; Tashiro M; Sata T; Kurata T; Hasegawa H
J Med Virol; 2012 Feb; 84(2):336-44. PubMed ID: 22170556
[TBL] [Abstract][Full Text] [Related]
6. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
[TBL] [Abstract][Full Text] [Related]
7. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
[TBL] [Abstract][Full Text] [Related]
9. IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.
Saito S; Sano K; Suzuki T; Ainai A; Taga Y; Ueno T; Tabata K; Saito K; Wada Y; Ohara Y; Takeyama H; Odagiri T; Kageyama T; Ogawa-Goto K; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
PLoS Pathog; 2019 Jan; 15(1):e1007427. PubMed ID: 30605488
[TBL] [Abstract][Full Text] [Related]
10. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
[TBL] [Abstract][Full Text] [Related]
11. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
[TBL] [Abstract][Full Text] [Related]
12. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.
Morokutti A; Muster T; Ferko B
Vaccine; 2014 Apr; 32(17):1897-900. PubMed ID: 24560674
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study.
Pan SC; Hsieh SM; Lin CF; Hsu YS; Chang M; Chang SC
Vaccine; 2019 Mar; 37(14):1994-2003. PubMed ID: 30837170
[TBL] [Abstract][Full Text] [Related]
14. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.
Moldoveanu Z; Clements ML; Prince SJ; Murphy BR; Mestecky J
Vaccine; 1995 Aug; 13(11):1006-12. PubMed ID: 8525683
[TBL] [Abstract][Full Text] [Related]
15. Nasal-subcutaneous prime-boost regimen for inactivated whole-virus influenza vaccine efficiently protects mice against both upper and lower respiratory tract infections.
Shibuya M; Tamiya S; Kawai A; Yoshioka Y
Biochem Biophys Res Commun; 2021 May; 554():166-172. PubMed ID: 33798943
[TBL] [Abstract][Full Text] [Related]
16. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.
Ainai A; Tamura S; Suzuki T; van Riet E; Ito R; Odagiri T; Tashiro M; Kurata T; Hasegawa H
Hum Vaccin Immunother; 2013 Sep; 9(9):1962-70. PubMed ID: 23896606
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination.
Manenti A; Tete SM; Mohn KG; Jul-Larsen Å; Gianchecchi E; Montomoli E; Brokstad KA; Cox RJ
Vaccine; 2017 Jan; 35(1):191-198. PubMed ID: 27789145
[TBL] [Abstract][Full Text] [Related]
18. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
19. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
20. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
Lambkin-Williams R; Gelder C; Broughton R; Mallett CP; Gilbert AS; Mann A; He D; Oxford JS; Burt D
PLoS One; 2016; 11(12):e0163089. PubMed ID: 28005959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
